David C. Klonoff

Aug 2, 2024 | healio.com | Michael Monostra |Richard Smith |David C. Klonoff

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Adults with type 2 diabetes or obesity using a GLP-1 had a similar risk for NAION as those using non-GLP-1 drugs.

Feb 7, 2024 | dovepress.com | David C. Klonoff |Brian Levy |Michael J. Jaasma |Manish Bharara

Back to Journals » Journal of Pain Research » Volume 17 Original Research Neuromodulation and Interventional Authors Klonoff DC , Levy BL, Jaasma MJ , Bharara M , Edgar DR, Nasr C, Caraway DL, Petersen EA , Armstrong DG Received 7 February 2024 Accepted for publication 31 July 2024 Published 18 September 2024 Volume 2024:17 Pages 3063—3074 DOI https://doi.org/10.2147/JPR.S463383 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved...

Nov 11, 2023 | ahajournals.org | Kershaw V. Patel |Matthew W. Segar |David C. Klonoff |Muhammad Khan

Background: The optimal approach to identify individuals with diabetes who are at high-risk for developing heart failure (HF) to inform implementation of preventive therapies is unknown, especially in those without atherosclerotic cardiovascular disease (ASCVD). Methods: Adults with diabetes and no HF at baseline from 7 community-based cohorts were included.